Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Advises QuantumCell ApS on Entering Out-Licensing and Collaboration Agreement With AlzeCure Pharma for Over $2.2 Billion

main

announcement-lifesciences-goodwin-advises-quantumcell-alzecure-pharma-2-2-billion-agreement

Goodwin's Life Sciences team advised QuantumCell on its licensing and collaboration agreement with AlzeCure Pharma valued at over $2.2 billion. Learn more.

Goodwin Advises QuantumCell ApS on Entering Out-Licensing and Collaboration Agreement With AlzeCure Pharma for Over $2.2 Billion | News & Events | Goodwin

Goodwin Advises QuantumCell ApS on Entering Out-Licensing and Collaboration Agreement With AlzeCure Pharma for Over $2.2 Billion

Related Content

340B Drug Rebate Pilot Program Revised by HRSA

Could States Create Their Own Pathways to Access Experimental Treatments? Montana May Be Testing the Limits of FDA’s Traditional Role

Celltrion Targets European Secukinumab Market with EMA Filing for CT-P55

Accord BioPharma Launches OSVYRTI® and JUBEREQ® Denosumab Biosimilars

Outlook Therapeutics Secures FDA Approval for LYTENAVA™

HHS Sets Timeline to End COVID-19 Emergency Use Authorizations

Formycon and OneSource Specialty Pharma Partner to Manufacture Biosimilars

Teva and Samsung Bioepis Enter Into Commercialization Agreement for OPUVIZ in Canada

Goodwin Pharma Services Symposium

Goodwin Advises Braveheart Bio on $439.9 Million Closing of Upsized Initial Public Offering

Goodwin Advises LifeMine Therapeutics on Raising $263M for a Safer Immunosuppressant

Goodwin’s Heath Ingram and Freddie Akrouche Named to Bloomberg Law’s They’ve Got Next: The 40 Under 40

Goodwin Advises Apnimed, Inc., on $220.8 Million IPO Including Full Exercise of the Underwriters’ Over-Allotment Option

Goodwin’s Niall Dickson, Heath Ingram, and Ben Reilly Named Law360 Rising Stars

Goodwin Guides Sail Biomedicines in Strategic Collaboration to Advance In Vivo CAR-T Medicines

Goodwin Advises Royalty Pharma on Acquiring Royalty Interest in AstraZeneca’s cliramitug for Up To $425 Million From Neurimmune

Life Sciences

Life Sciences Collaborations & Licensing